Connect with others who understand.

  •   Learn from expert-reviewed resources
  •   Real advice from people who’ve been there
  •   People who understand what you’re going through
Sign Up Log In
Powered By
Real members of myPHteam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.
A myPHteam Member asked a question 💭
San Jose, CA
June 13, 2024
 · 
Be the first to react
A myPHteam Member

I was diagnosed January 2022. Started Adempas soon after. I did have a few side effects that I worked through. I feel much better now. I also take Uptravi. The fluid pills as needed. Not sure what your question was.

June 14, 2024
myPHteam

Adempas (Riociguat) is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to improve exercise and function in adult cases of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Here are some key points about Adempas:

- Class: Soluble guanylate cyclase Show Full Answer

Adempas (Riociguat) is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to improve exercise and function in adult cases of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Here are some key points about Adempas:

- Class: Soluble guanylate cyclase stimulators (SGCS).
- Mechanism: Stimulates the action of an enzyme called soluble guanylate cyclase, which dilates blood vessels, specifically the pulmonary arteries.
- Dosage: Taken three times a day in tablet form.
- Side Effects: Common side effects include headache, dizziness, low blood pressure, upset stomach, stomach pain, anemia, gastric reflux, nausea, diarrhea, vomiting, and constipation. Rare but serious side effects include severe birth defects, bleeding, severe hypotension, and pulmonary edema.
- Special Program: Due to its potential to cause severe birth defects, Adempas is only available to female consumers through a limited distribution program called the Adempas Risk Evaluation and Mitigation Strategies (REMS) Program.

For more details, you can visit the [Adempas page on myPHteam](https://www.myPHteam.com/treatments/adempas).

June 13, 2024
Continue with Facebook
Continue with Google
By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data and Privacy policies.
Already a member? Log In